Your browser doesn't support javascript.
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.
Abdul-Jawad, Sultan; Baù, Luca; Alaguthurai, Thanussuyah; Del Molino Del Barrio, Irene; Laing, Adam G; Hayday, Thomas S; Monin, Leticia; Muñoz-Ruiz, Miguel; McDonald, Louisa; Francos Quijorna, Isaac; McKenzie, Duncan; Davis, Richard; Lorenc, Anna; Chan, Julie Nuo En; Ryan, Sarah; Bugallo-Blanco, Eva; Yorke, Rozalyn; Kamdar, Shraddha; Fish, Matthew; Zlatareva, Iva; Vantourout, Pierre; Jennings, Aislinn; Gee, Sarah; Doores, Katie; Bailey, Katharine; Hazell, Sophie; De Naurois, Julien; Moss, Charlotte; Russell, Beth; Khan, Aadil A; Rowley, Mark; Benjamin, Reuben; Enting, Deborah; Alrifai, Doraid; Wu, Yin; Zhou, You; Barber, Paul; Ng, Tony; Spicer, James; Van Hemelrijck, Mieke; Kumar, Mayur; Vidler, Jennifer; Lwin, Yadanar; Fields, Paul; Karagiannis, Sophia N; Coolen, Anthony C C; Rigg, Anne; Papa, Sophie; Hayday, Adrian C; Patten, Piers E M.
  • Abdul-Jawad S; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Baù L; Institute of Biomedical Engineering, University of Oxford, Oxford, UK.
  • Alaguthurai T; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Breast Cancer Now Research Unit, King's College London, London, UK.
  • Del Molino Del Barrio I; Cancer Immunotherapy Accelerator, UCL Cancer Institute, University College and King's College, London, UK; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Laing AG; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Hayday TS; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Monin L; The Francis Crick Institute, London, UK.
  • Muñoz-Ruiz M; The Francis Crick Institute, London, UK.
  • McDonald L; Oncology and Haematology Clinical Trials (OHCT), Guy's and St Thomas' NHS Foundation Trust, London UK.
  • Francos Quijorna I; Wolfson Centre for Age-Related Diseases, IoPPN, King's College London, London, UK.
  • McKenzie D; The Francis Crick Institute, London, UK.
  • Davis R; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Lorenc A; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Chan JNE; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Ryan S; Department of Inflammation Biology, King's College London, London, UK.
  • Bugallo-Blanco E; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Yorke R; Department of Inflammation Biology, King's College London, London, UK.
  • Kamdar S; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Fish M; Peter Gorer Department of Immunobiology, King's College London, London, UK; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Zlatareva I; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Vantourout P; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Jennings A; Peter Gorer Department of Immunobiology, King's College London, London, UK; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Gee S; Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • Doores K; Department of Infectious Diseases, King's College London, London, UK.
  • Bailey K; Department of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.
  • Hazell S; Department of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.
  • De Naurois J; Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Moss C; Department of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • Russell B; Department of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • Khan AA; Targeted Therapy Team, The Institute of Cancer Research, London, UK.
  • Rowley M; London Institute for Mathematical Sciences, Mayfair, London, UK; Saddle Point Science Ltd, London, UK.
  • Benjamin R; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematological Medicine, King's College Hospital, London, UK.
  • Enting D; Department of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • Alrifai D; Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Wu Y; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Cancer Immunotherapy Accelerator, UCL Cancer Institute, University College and King's College, London, UK; Peter Gorer Department of Immunobiology, King's College London, London, UK; The Francis Crick Institute, Londo
  • Zhou Y; Systems Immunity University Research Institute and Division of Infection and Immunity, Cardiff University, Cardiff, UK.
  • Barber P; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Ng T; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Spicer J; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Van Hemelrijck M; Department of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • Kumar M; Department of Gastroenterology, Princess Royal University Hospital, Kent, UK.
  • Vidler J; Department of Haematological Medicine, King's College Hospital, London, UK.
  • Lwin Y; Department of Haematological Medicine, King's College Hospital, London, UK.
  • Fields P; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.
  • Karagiannis SN; Breast Cancer Now Research Unit, King's College London, London, UK; St. John's Institute of Dermatology, King's College London, London, UK; NIHR Biomedical Research Centre, and King's College London, London, UK.
  • Coolen ACC; Targeted Therapy Team, The Institute of Cancer Research, London, UK; London Institute for Mathematical Sciences, Mayfair, London, UK; Saddle Point Science Ltd, London, UK; Department of Biophysics, Radboud University, Nijmegen, The Netherlands.
  • Rigg A; Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Papa S; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Hayday AC; Peter Gorer Department of Immunobiology, King's College London, London, UK; The Francis Crick Institute, London, UK.
  • Patten PEM; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematological Medicine, King's College Hospital, London, UK; Medical Research Council (MRC) Clinical Academic Research Partnership, London, UK.
Cancer Cell ; 39(2): 257-275.e6, 2021 02 08.
Article in English | MEDLINE | ID: covidwho-1009339
Semantic information from SemMedBD (by NLM)
1. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
2. IMPACT gene PART_OF 2019 novel coronavirus
Subject
IMPACT gene
Predicate
PART_OF
Object
2019 novel coronavirus
3. Hematologic Neoplasms PROCESS_OF Patients
Subject
Hematologic Neoplasms
Predicate
PROCESS_OF
Object
Patients
4. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
5. IMPACT gene PART_OF 2019 novel coronavirus
Subject
IMPACT gene
Predicate
PART_OF
Object
2019 novel coronavirus
6. Hematologic Neoplasms PROCESS_OF Patients
Subject
Hematologic Neoplasms
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe Acute Respiratory Syndrome / COVID-19 / Neoplasms Type of study: Etiology study / Risk factors Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cancer Cell Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: J.ccell.2021.01.001

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe Acute Respiratory Syndrome / COVID-19 / Neoplasms Type of study: Etiology study / Risk factors Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cancer Cell Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: J.ccell.2021.01.001